Personalized cell therapy takes on GI cancers

NCT ID NCT03614650

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment for gastrointestinal cancer using a patient's own immune cells, which are engineered in a lab to target cancer. About 100 participants will receive these cells to see if they are safe and can shrink tumors. The trial is currently recruiting and combines early safety testing with initial effectiveness checks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: engineered immune cells
What this could lead to: If successful, this could point toward a new treatment option for gastrointestinal cancers using the patient's own immune cells.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 100 participants, so results may not apply broadly. Side effects from the cell therapy are possible and are being closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer digestive system cancer digestive system neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

Shenzhen Geno-immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.